Childhood Absence Epilepsy Treatment Market Research Report 2018: Pfizer, Inc., GlaxoSmithKline Plc, Insys Therapeutics, Inc., AbbVie, Inc., and Teva Pharmaceutical Industries Ltd

According to various studies published by the National Center for Biotechnology Information and recent recommendation by the National Institute for Health and Care Excellence (NICE), 2018, Ethosuximide should be considered as a first choice of treatment, followed by Valproate and Lamotrigine. Moreover, various manufacturers such as Insys Therapeutics (Cannabidiol) and Cavion, Inc. (CX-8998) have drugs in phase II stage in clinical trials and these therapies are expected to be launched over the forecast period. Availability of generic versions of drugs are expected to increase accessibility and affordability of the treatment. Ethosuximide is taken orally and generic versions of Ethosuximide are available in the market. Other manufacturers such as Akorn, Inc., Bionpharma, Inc., and Teva Pharmaceuticals USA manufacture Ethosuximide in various dosage forms such as capsule and syrup. These factors are expected to drive the global childhood absence epilepsy treatment market growth over the forecast period.

Request a Sample Copy @ www.coherentmarketinsights.com/insight/request-sample/2329

Manufacturers are indulged in launching generic versions of drugs in developed as well as emerging economies. For instance, Greenstone, LLC, a generic pharmaceutical company and a wholly owned subsidiary of Pfizer Inc., launched authorized generic (Pfizer's own generic version) of Zarontin capsules and oral solution in 2015. Dr. Reddy’s Laboratories launched generic lamotrigine orally disintegrating tablets in the U.S. in 2016. Moreover, Handa Pharmaceuticals, Inc. announced that TruPharma, LLC started to market and distribute Handa’s FDA-approved Abbreviated New Drug Application for Lamotrigine Extended Release Tablets in the U.S. in 2017. Mylan Laboratories as well as Wockhardt launched generic versions of Lamictal in 2014 and 2013, respectively.

Market Dynamics

Key players in the market are focused on the development of new drugs for the treatment of childhood absence epilepsy. Factors such as increasing prevalence of the disease, increasing accessibility of medications, and presence of drugs in pipeline for childhood absence epilepsy treatment (Insys therapeutics and Cavion, Inc.) are expected to boost the global childhood absence epilepsy treatment market growth. Product launches by generic manufacturers in the U.S. as well as globally is expected to support growth of the market. For instance, Dr. Reddy’s Laboratories launched generic lamotrigine orally disintegrating tablets in the U.S. in 2016. Moreover, a number of manufacturers such as Insys Therapeutics (Cannabidiol) and Cavion, Inc. (CX-8998) have drugs in phase II stage in clinical trials and these therapies are expected to be launched over the forecast period.

Some of the major players operating in the global childhood absence epilepsy treatment market include Cavion, Inc., Pfizer, Inc., GlaxoSmithKline Plc, Insys Therapeutics, Inc., AbbVie, Inc., and Teva Pharmaceutical Industries Ltd.

Download PDF Brochure @ www.coherentmarketinsights.com/insight/request-pdf/2329

Detailed Segmentation:

Global Childhood Absence Epilepsy Treatment Market, By Drug:
Ethosuximide
Valproate
Lamotrigine
Phase 2 Drugs
Cannabidiol Oral Solution
CX-8998
Global Childhood Absence Epilepsy Treatment Market, By Disease Type:
Typical Absence Seizures
Atypical Absence Seizures

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

1001 4th Ave,, #3200, Seattle, WA 98154

This release was published on openPR.